846589-98-8 Usage
Description
(R)-1H-3-Benzazepine,8-chloro-2,3,4,5-tetrahydro-1-methyl-, hydrochloride, also known as lorcaserin hydrochloride, is a selective serotonin 5-HT2C receptor agonist. It was approved by the US FDA in June 2012 for chronic weight management in adult patients who are overweight or obese and have at least one comorbid, weight-related condition. Lorcaserin works by regulating appetite and feeding behavior through its action on the 5-HT2C receptor, which is primarily found in the hypothalamus. The benzazepine ring in lorcaserin improves its selectivity for the 5-HT2C receptor, reducing safety concerns associated with previous 5-HT2C agonists.
Uses
Used in Pharmaceutical Industry:
Lorcaserin hydrochloride is used as an antiobesity drug for the treatment of chronic weight management in adult patients who are overweight or obese and have at least one weight-related comorbid condition. It acts as a selective serotonin 5-HT2C receptor agonist, helping to regulate appetite and feeding behavior.
Used in Research and Forensic Applications:
Lorcaserin (hydrochloride) (CRM) is a certified reference material categorized as an anorectic. It is used in research and forensic applications to study its effects on decreasing oxycodone intake and its positive impact on self-administration and relapse vulnerability in rats. Lorcaserin is regulated as a Schedule IV compound in the United States, ensuring its proper use and distribution in these applications.
Originator
Pharmaceuticals (United States)
Side effects
Lorcaserin hydrochloride (Belviq) is a serotonin 2C receptor agonist that causes weight loss by causing appetite suppression.It appears to have fewer adverse effects than orlistat,although long-term safety data are limited. The recommended dosage is 10mg twice daily. Lorcaserin should be discontinued if patients do not lose 5% of their body weight in 12 weeks. The efficacy of lorcaserin appears similar to that of orlistat (mean difference in weight loss between active and placebo-treated groups approximately 3-4 kg).Common side effects include nausea, headache,dizziness, nasopharyngitis, and fatigue. Lorcaserin may increasethe risk of symptomatic hypoglycemia in patients with type 2 diabetes on oral agents, necessitating a reduction in the dose of diabetes medications. Lorcaserin should not be used in individuals with creatinine clearance <30 mL/minute. It is contraindicated during pregnancy. In addition, lorcaserin should not be used with other serotonergic drugs (e.g., selective serotonin reuptake inhibitors,selective serotonin-norepinephrine reuptake inhibitors, bupropion[Wellbutrin], tricyclic antidepressants,and monamine oxidase inhibitors)because of the theoretical potential for serotonin syndrome.https://www.accessdata.fda.govhttps://medlineplus.gov
Check Digit Verification of cas no
The CAS Registry Mumber 846589-98-8 includes 9 digits separated into 3 groups by hyphens. The first part of the number,starting from the left, has 6 digits, 8,4,6,5,8 and 9 respectively; the second part has 2 digits, 9 and 8 respectively.
Calculate Digit Verification of CAS Registry Number 846589-98:
(8*8)+(7*4)+(6*6)+(5*5)+(4*8)+(3*9)+(2*9)+(1*8)=238
238 % 10 = 8
So 846589-98-8 is a valid CAS Registry Number.
846589-98-8Relevant articles and documents
Method for preparing lorcaserin
-
Paragraph 0035; 0037-0039; 0041-0043, (2020/08/22)
The invention discloses a method for preparing lorcaserin. Specifically, the method comprises the steps: taking p-chlorophenylacetonitrile as an initial raw material, preparing p-chlorophenylethylamine through reduction; carrying out a reaction with p-toluenesulfonyl chloride to form an amino occupying intermediate; enabling the intermediate to carry out a reaction with monochloroacetone under analkaline condition to form N-(2-(4-chlorphenyl)ethyl)-4-methyl-N-(2-propionyl)benzenesulfonamide, and then carrying out reduction, chlorination, p-toluenesulfonyl removal and intramolecular Friedel-Crafts alkylation to synthesize 8-chloro-1-methyl-2,3,4,5-tetrahydro-1H-3-benzoazepine, carrying out L-(+)-tartaric acid resolution and alkalization on azepine to remove tartaric acid, and acting with hydrogen chloride diethyl ether to salify to prepare lorcaserin. The method has the characteristics of simple synthesis method, good reaction selectivity, high product purity, environmental protectionand low preparation cost.
A new enantioselective synthesis of antiobesity drug lorcaserin
Ghotekar, Ganesh S.,More, Devidas A.,Nalla, Viswanadh,Muthukrishnan
, p. 16876 - 16880 (2019/11/14)
A simple and efficient enantioselective synthesis of anti-obesity drug lorcaerin starting from easily accessible 3-chlorostyrene oxide has been described for the first time employing hydrolytic kinetic resolution as a source of chirality. The protocol might also be useful in the synthesis of structural variants of lorcaserin.
MODIFIED-RELEASE DOSAGE FORMS OF 5-HT2C AGONISTS USEFUL FOR WEIGHT MANAGEMENT
-
Paragraph 1182-1186; 1189-1192; 1197, (2019/05/30)
The present invention relates to methods for weight management that utilize modified-release dosage forms comprising (R)-8-chloro-1-methyl-2,3,4,5-tetrahydro-1H-3-benzazepine salts and crystalline forms thereof. The present invention further relates to (R)-8-chloro-1-methyl-2,3,4,5-tetrahydro-1H-3-benzazepine salts, crystalline forms thereof and modified-release dosage forms comprising them.